Cost-effectiveness of nintedanib versus Pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review [0.03%]
治疗特发性肺纤维化时，尼达尼布相对于吡非尼酮的成本效果对比：系统性回顾
Aziz Rezapour,Mohammad Veysi-Sheykhrobat,Aghdas Souresrafil et al.
Aziz Rezapour et al.
Introduction: Objective: To systematically review studies on the cost-effectiveness of pirfenidone compared to nintedanib in patients with idiopathic pulmonary fibrosis (IPF). ...
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China [0.03%]
公立医院综合改革对慢性阻塞性肺疾病患者经济负担影响研究——西部试点城市数据分析
Yanghaotian Wu,Jingfu Qiu
Yanghaotian Wu
Background: The Chinese government launched a comprehensive reform of public hospitals, including a zero-markup drug policy (ZMDP) and adjustments to the price compensation mechanism for medical services. We aimed to asse...
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update [0.03%]
欧盟罕见疾病患者药物的获取与定价：行业视角。2025年更新版
Giovanni Tafuri,Andrea Bracco,Jens Grueger
Giovanni Tafuri
Introduction: In a previous publication, we provided an overview of the current situation of patient access to orphan drugs in the European Union (EU), of the evolving rare disease policy landscape and recommendations for...
Psychometric properties of outcome measures for freezing of gait in Parkinson's disease: a systematic review and meta-analysis [0.03%]
帕金森病冻结步态结局测量指标的心理测量属性：系统评价和荟萃分析
Prisca Proietti,Ilaria Ruotolo,Alessandra Carlizza et al.
Prisca Proietti et al.
Introduction: This systematic review and meta-analysis aimed to evaluate validated tools for assessing FOG in individuals with PD, focusing on their psychometric properties, linguistic adaptations, and methodological qual...
Ana Bobinac,Luka Vončina,Ismar Velić et al.
Ana Bobinac et al.
Background: Rising pharmaceutical expenditure worldwide, including in Croatia, is putting considerable pressure on healthcare budgets. Oncology drugs, often used in several indications with varying efficacy, contribute to...
Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China [0.03%]
在中国广泛期小细胞肺癌患者中，特利帕肽用于减少化疗引起的骨髓抑制发生率的成本效益分析
Nan Fang,Xuan Xia,Xiaoning He
Nan Fang
Background: Chemotherapy-induced myelosuppression (CIM) is the most common adverse event associated with chemotherapy. The recently approved novel pharmacotherapy trilaciclib demonstrates potential to provide multilineage...
Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities [0.03%]
意大利2022年生物药物消费评估：两家医疗机构之间的比较分析
Marcello Vaccaro,Giacomo Polito,Gabriele Bagaglini et al.
Marcello Vaccaro et al.
Background: Biosimilar drugs represent a valuable opportunity for healthcare systems worldwide as they offer substantial cost savings. This retrospective observational study aimed to assess the current prescribing trend i...
Patient-Relevance of Outcome Measures in Breast Cancer Clinical Trials: A Cross-Sectional Comparative Analysis of Patient Preferences and Trials Conducted Between 2014 and 2024 [0.03%]
乳腺癌临床试验中结局指标的患者相关性：一项横断面比较分析患者偏好和2014年至2024年间进行的试验
Jasmijn Plooij,Diana M J Delnoij
Jasmijn Plooij
Background: Worldwide, many clinical trials are performed using clinical outcomes and surrogate outcomes as endpoints. Surrogate outcomes are used, for instance, if there is not enough follow-up time to measure the outcom...
Cost comparison of F(ab')2 and fab antivenoms for pit viper envenomation in the United States: a Real-World Analysis [0.03%]
美国响尾蛇咬伤的F（ab'）2和Fab抗蛇毒血清成本比较：真实世界分析
Walter Garcia-Ubbelohde,Lia Pizzicato,Keith Boesen et al.
Walter Garcia-Ubbelohde et al.
Background: This study compared healthcare resource utilization (HCRU) and cost among patients treated for pit viper envenomation with Fab or F(ab')2 antivenom in the United States. ...
Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis [0.03%]
自体干细胞移植和维持治疗适合移植的多发性骨髓瘤患者的成本效益分析：基于网状Meta分析
Weijia Wu,Yannan Wang,Yingting Lou et al.
Weijia Wu et al.
Background: This study aimed to evaluate the cost-effectiveness of ASCT and maintenance therapy strategies for transplant-eligible patients with newly diagnosed multiple myeloma from a Chinese healthcare perspective. ...